As of November 4, 2026, Estrella Immunopharma, Inc. is a publicly traded company (Nasdaq: ESLA). The largest insider holding is Cheng Liu, the chief executive and a director, with 397,437 shares (0.91% of shares outstanding), per Form 4 of August 26, 2026. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13G, May 15, 2026).
Is this your company?
About to sign with, pay or invest in Estrella Immunopharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Estrella Immunopharma, Inc. a real, registered company?
- Estrella Immunopharma, Inc. files with the SEC under CIK 1844417 (its SEC filings).
- Its shares are listed under the ticker ESLA on Nasdaq (also ESLAW) (SEC company record).
- business address in Emeryville, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ESTRELLA IMMUNOPHARMA, INC. in our court records and SEC 8-K records (as of 2026-11-04).
- Leadership changes: the latest reported is Cynthia Pussinen, Chief Executive Officer (Form 8-K filed 2026-10-29). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-05-15).
Who are Estrella Immunopharma, Inc.'s owners and officers?
Estrella Immunopharma, Inc.: business address in Emeryville, California; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-10-29).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 4.99% |
| Schedule 13G, 2026-05-15 | Armistice Capital, LLC | 9.99% |
Want the whole picture on Estrella Immunopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Estrella Immunopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Estrella Immunopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-29 | Cynthia Pussinen | Chief Executive Officer | appointed | 2026-10-25 |
Which insiders own Estrella Immunopharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 397,437 shares (0.91% of shares outstanding) (Form 4, 2026-08-26).
- , the chief financial officer: 365,488 shares (0.84% of shares outstanding) (Form 4, 2026-08-25).
Shares outstanding: 43,497,864 as of 2026-08-11, from the company's latest SEC cover page.
How much has Estrella Immunopharma, Inc. raised?
Latest IPO step: Estrella Immunopharma, Inc. amended its IPO registration (S-1/A, 2026-01-22).
IPO filings: S-1/A, 2026-01-22, S-1/A, 2026-01-16, S-1, 2025-12-22.
Keep reading
More on Estrella Immunopharma, Inc. and the records around it.
Estrella Immunopharma, Inc. elsewhere on the record
- Leadership changes Oct 2026
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/estrella-immunopharma